GlobalData on MSN

Akeso’s PD-1/CTLA-4 bispecific trumps chemo in frontline gastric cancer

Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
Cancer Therapy Advisor

FDA Grants Fast Track Status to BNT113 for HPV16+ Head and Neck Cancer

The FDA's Fast Track designation helps to accelerate the development and review of products for serious and life-threatening conditions.
Medical News Today

Treatment guide: Subcutaneous PD-1 or PD-L1 inhibitor injections for treating cancer

PD-1 and PD-L1 inhibitors are types of immune checkpoint inhibitors, which are immunotherapy medications for treating cancer. Immunotherapy helps the immune system find and kill cancer cells. Some ...
Antelope Valley Press

Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), ...
Morningstar

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative ...

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients FDA priority ...
PMLive

Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer

Gilead has announced full results from its study of Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) as a first ...
Nasdaq

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

AUSTIN, Texas, Aug. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients ...

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1 ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...
STAT

Cancer therapy’s new ‘gold rush’: bispecific antibodies that hit key combination of targets

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...